Table 3.
Kaplan-Meier analysis of asexual and sexual parasite survival amongst patients at two locations according to treatment regimen, Colombia
| Treatment | Days with asexual parasites | Days with gametocytes | ||||
|---|---|---|---|---|---|---|
| Turbo | El Bagre | Log-rank test P | Turbo | El Bagre | Log-rank test P | |
| Mean (95% CI)* | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | |||
| CQ and SP | 4 (2–6) | 4 (2–6) | 0.9319 | 19 (17–20) | 19 (18–21) | 0.4875 |
| AQ and SP | 2 (1–2) | 2 (1–3) | 0.3864 | 12 (9–15) | 16 (14–18) | 0.0780 |
| MQ and SP | 3 (1–5) | 2 (1–2) | 0.2336 | 12 (9–16) | 11 (8–14) | 0.3824 |
| AS and SP | 1 (1–1) | 1 (1–1) | 0.5148 | 6 (3–8) | 4 (2–7) | 0.5057 |
*
CI = confidence interval; Log-rank test = a test for comparing parasite survival between two places; CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine; MQ = mefloquine; AS = artesunate.